Gilead Sciences (NQ:GILD)

144.74 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

78 79 Next >

FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

February 06, 2026

From Gilead Sciences, Inc.

Via Business Wire

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 5 Years ↗

February 05, 2026

Via Benzinga

This Overlooked Biotech Giant Could Surprise Investors This Quarter

February 05, 2026

Investors may be underestimating the long-term potential of Gilead’s evolving portfolio.

Via Barchart.com

1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Challenges

February 02, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Gilead Sciences Inc. (NASDAQ:GILD) Passes the Caviar Cruise Quality Investing Screen ↗

January 22, 2026

Via Chartmill

GILEAD SCIENCES INC (NASDAQ:GILD): A High-Yield, Low-Payout Dividend Stock for Disciplined Investors ↗

January 20, 2026

Via Chartmill

Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide

February 02, 2026

Via PRLog

Large Cap Biopharmaceuticals: A Core Position For A Healthcare Portfolio ↗

February 02, 2026

Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following...

Via Talk Markets

Topics Stocks

3 Cash-Producing Stocks with Warning Signs

January 29, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

The Commonwealth Club Honors Black History Month With Event Featuring Top Black Leaders in AI & Biopharma Discussing the Future of Healthcare

January 29, 2026

Via Get News

Topics Artificial Intelligence

Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?

January 29, 2026

Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Via Barchart.com

Topics ETFs

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

January 27, 2026

From Gilead Sciences, Inc.

Via Business Wire

Demystifying Gilead Sciences: Insights From 17 Analyst Reviews ↗

January 27, 2026

Via Benzinga

Exploring the top movers within the S&P500 index during today's session. ↗

January 23, 2026

Via Chartmill

Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today ↗

January 22, 2026

Via Benzinga

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

January 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Earnings Preview: What to Expect

January 19, 2026

Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS.

Via Barchart.com

Topics Artificial Intelligence ETFs Government

Looking Into Gilead Sciences Inc's Recent Short Interest ↗

January 16, 2026

Via Benzinga

A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)

January 13, 2026

Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage...

Via PredictStreet

Topics Economy Initial Public Offering

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?

January 05, 2026

Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 10.1%.

Via StockStory

Topics Stocks

U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗

January 05, 2026

Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.

Via Stocktwits

Topics Government

3 Cash-Flow Machines Investors May Want Heading Into 2026 ↗

January 02, 2026

Via MarketBeat

Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today ↗

January 01, 2026

Via Benzinga

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value

December 31, 2025

As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

What's Driving the Market Sentiment Around Gilead Sciences Inc? ↗

December 31, 2025

Via Benzinga

Stock Index Futures Slip in Weak End to a Banner Year

December 31, 2025

March S&P 500 E-Mini futures (ESH26) are down -0.20%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.32% this morning, pointing to a weak start on Wall Street in the final trading session of...

Via Barchart.com

Topics Bonds Government Stocks

Discover which S&P500 stocks are making waves on Tuesday. ↗

December 30, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.